The Progression of Renal Disease

New England Journal of Medicine

Volumn 318, Issue 25, 1988, Pages 1657-1666

  Epstein, Franklin H ^a   Klahr, Saulo ^b   Schreiner, George ^b   Ichikawa, Iekuni ^b  

^a Division of Pediatric Nephrology ^*

^b University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; GLOMERULOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW;

HUMAN; KIDNEY DISEASES; KIDNEY GLOMERULUS; SCLEROSIS;

EID: 0023906655     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198806233182505     Document Type: Review

References (60)

1. Goldszer RC, Sweet J, Cotran RS. Focal segmental glomerulosclerosis. Annu Rev Med 1984; 35: 429–49.
2. Halevy J, Hayslett JP. Clinical features and course of glomerulosclerosis. In: Mitch WE, Brenner BM, Stein JH, eds. The progressive nature of renal disease. New York: Churchill Livingstone, 1986:189–201.
3. Kaplan C, Pasternack B, Shah H, Gallo G. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975; 80: 227–34.
4. Abrahamson DR. Structure and development of the glomerular capillary wall and basement membrane. Am J Physiol 1987; 253: F783–F794.
5. Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J 1987; 1: 272–81.
6. Schreiner GF, Unanue ER. Origin of the rat mesangial phagocyte and its expression of the leukocyte common antigen. Lab Invest 1984; 51: 515–23.
7. Haralson MA, Hoover RL, Jacobson HR. Cultured rat kidney mesangial cells synthesize predominantly the trimeric form of type I collagen. Kidney Int 1988; 33: 158. abstract.
8. Schreiner GF, Cotran RS, Unanue ER. Macrophages and cellular immunity in experimental glomerulonephritis. Springer Semin Immunopathol 1982; 5: 251–67.
9. Bolton WK, Innes DJ Jr, Sturgill BC, Kaiser DL. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int 1987; 32: 869–76.
10. Hooke DH, Hancock WW, Gee DC, Kraft N, Atkins RC. Monoclonal antibody analysis of glomerular hypercellularity in human glomerulonephritis. Clin Nephrol 1984; 22: 163–8.
11. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79: 319–26.
12. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618–23.
13. Barnes JL, Venkatachalam MA. The role of platelets and polycationic mediators in glomerular vascular injury. Semin Nephrol 1985; 5: 57–68.
14. Schlondorff D, Neuwirth R. Platelet-activating factor and the kidney. Am J Physiol 1986; 251: F1–F11.
15. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 97–145.
16. Williams LT. Stimulation of paracrine and autocrine pathways of cell proliferation by platelet-derived growth factor. Clin Res 1988; 36: 5–10.
17. Dunn MJ, Renal prostaglandins. In: Klahr S, Massry SG, eds. Contemporary nephrology. Vol. 4. New York: Plenum Press, 1987:165–8.
18. Werber HI, Emancipator SN, Tykocinski ML, Sedor JR. The interleukin I gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J Immunol 1987; 138: 3207–12.
19. Velosa JA, Glasser RJ, Nevins TE, Michael AF. Experimental model of focal sclerosis. II. Correlation with immunopathologic changes, macromolecular kinetics, and polyanion loss. Lab Invest 1977; 36: 527–34.
20. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987; 32: 691–9.
21. Schreiner GF, Cotran RS, Unanue ER. Modulation of Ia and leukocyte common antigen expression in rat glomeruli during the course of glomerulonephritis and aminonucleoside nephrosis. Lab Invest 1984; 51: 524–33.
22. Grond J, Koudstaal J, Elema JD. Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis. Kidney Int 1985; 27: 405–10.
23. Fogo A, Yoshida Y, Glick AD, et al. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest (in press).
24. Mynderse LA, Hassell JR, Kleinman HK, Martin GR, Martinez-Hernandez A. Loss of heparan sulfate proteoglycan from glomerular basement membrane of nephrotic rats. Lab Invest 1983; 48: 292–302.
25. Kaysen GA, Myers BD, Couser WG, Rabkin R, Felts JM. Mechanisms and consequences of proteinuria. Lab Invest 1986; 54: 479–98.
26. Masugi Y, Masuda Y, Sato S, Ishizaki M, Sawaguchi H. Retarded mesangial transport and its pathomorphologic sequelae in human and experimental renal diseases. Acta Pathol Jpn 1983; 33: 219–36.
27. Davies DJ, Brewer DB, Hardwicke J. Urinary proteins and glomerular morphometry in protein overload proteinuria. Lab Invest 1978; 38: 232–43.
28. Castellot JJ Jr, Hoover RL, Harper PA, Karnovsky MJ. Heparin and glomerular epithelial cell-secreted heparinlike species inhibit mesangial-cell proliferation. Am J Pathol 1985; 120: 427–35.
29. Diamond JR, Karnovsky MJ. Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. Renal Physiol 1986; 9: 366–74.
30. Purkerson ML, Tollefsen DM, Klahr S. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 1988; 81: 69–74.
31. Klahr S, Heifets M, Purkerson ML. The influence of anticoagulation on the progression of experimental renal disease. In: Mitch WE, Brenner BM, Stein JH, eds. The progressive nature of renal disease. New York: Churchill Livingstone, 1986:45–64.
32. Ichikawa I, Yoshida Y, Purkerson ML, Klahr S. Effect of heparin administration on the glomerular structure and function of remnant nephrons. J Hypertens 1986; 4: Suppl: S567. abstract.
33. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249: F324–F337.
34. Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 1985; 82: 193–7.
35. Hakim RM, Goldszer RC, Brenner BM. Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Kidney Int 1984; 25: 930–6.
36. Raij L, Keane WF. Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 1985; 79: Suppl 3C: 24–30.
37. Norman J, Badie-Dexfooly B, Nord EP, et al. EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physiol 1987; 253: F299–F309.
38. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–20.
39. Hommel E, Parving H-H, Mathiesen E. Edsberg B, Nielsen MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293: 467–70.
40. Baldwin DS, Neugarten J. Blood pressure control and progression of renal insufficiency. In: Mitch WE, Brenner BM, Stein JH, eds. The progressive nature of renal disease. New York: Churchill Livingstone, 1986:81–110.
41. Klahr S, Tripathy K. Evaluation of renal function in malnutrition. Arch Intern Med 1966; 118: 322–5.
42. Agus D, Mann R, Cohn D, et al. Inhibitory role of dietary protein restriction on the development and expression of immune-mediated antitubular basement membrane-induced tubulointerstitial nephritis in rats. J Clin Invest 1985; 76: 930–6.
43. Ichikawa I, Purkerson ML, Yates J, Klahr S. Dietary protein intake conditions the degree of renal vasoconstriction in acute renal failure caused by ureteral obstruction. Am J Physiol 1985; 249: F54–F61.
44. Moorehead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309–11.
45. Alderson LM. Endemann G, Lindsey S, Pronczuk A, Hoover RL, Hayes KC. LDL enhances monocyte adhesion to endothelial cells in vitro. Am J Pathol 1986; 123: 334–42.
46. Keane WF, Kasiske BL, O'Donnell MP. Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 1988; 47: 157–60.
47. Heifets M, Davis TA, Tegtmeyer E, Klahr S. Exercise training ameliorates progressive renal disease in rats with subtotal nephrectomy. Kidney Int 1987; 32: 815–20.
48. Teodoru CV, Saifer A, Frankel H. Conditioning factors influencing evolution of experimental glomerulonephritis in rabbits. Am J Physiol 1959; 196: 457–60.
49. Glasser RJ, Velosa JA, Michael AF. Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest 1977; 36: 519–26.
50. Steffes MW, Brown DM, Mauer SM. Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes 1978; 27: 35–41.
51. Seyer-Hansen K, Hansen J, Gundersen HJG. Renal hypertrophy in experimental diabetes: a morphometric study. Diabetologia 1980; 18: 501–5.
52. Mauer SM, Steffes MW, Azar S, Sandberg SK, Brown DM. The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat. Diabetes 1978; 27: 738–44.
53. Werb Z. Biochemical actions of glucocorticoids on macrophages in culture: specific inhibition of elastase, collagenase, and plasminogen activator secretion and effects on other metabolic functions. J Exp Med 1978; 147: 1695–712.
54. Ichikawa I, Purkerson ML, Klahr S, Troy JL, Martinez-Maldonado M, Brenner BM, Mechanism of reduced glomerular filtration rate in chronic malnutrition. J Clin Invest 1980; 65: 982–8.
55. Halliburton IW, Thomson RY. Chemical aspects of compensatory renal hypertrophy. Cancer Res 1965; 25: 1882–7.
56. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963–7.
57. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612–9.
58. Yoshida Y, Fogo A, Ichikawa I. Glomerular hypertrophy has a greater impact on glomerular sclerosis than the adaptive hyperfunction in remnant nephrons. Kidney Int 1988; 33: 327. abstract.
59. Fogo A, Yoshida Y, Ichikawa I, et al. Hypertrophic glomeruli and possible relationship to glomerular sclerosis. Lab Invest 1988; 58: 31a. abstract.
60. Ichikawa I, Yoshida Y, Fogo A. Glomerular hyperfiltration, hyperperfusion or hypertension does not mediate the hypertrophy of glomeruli which predisposes to sclerosis. Kidney Int 1988; 33: 377. abstract.